Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
(NASDAQ: NTRA) Delayed: 366.31 +20.97 (6.07%)
Previous Close $345.34    52 Week High $13.80 
Open $350.50    52 Week Low $6.52 
Day High $366.70    P/E N/A 
Day Low $348.26    EPS $0.00 
Volume 2,560,842